Physician profile
Jonathan B Levyn
NPI 1487697405
$14,191.26
in general payments reported to CMS, 2019-2025
51 companies · $2,139 in 2025
The $2,139 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $1,685 · 2021: $2,304 · 2022: $2,200 · 2023: $2,337 · 2024: $1,949 · 2025: $2,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,424.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,925.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,557.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,320.98 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,013.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $981.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $633.28 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $538.02 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $391.41 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $341.10 | 2020-2022 | |
| Allergan, INC. | $340.22 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $301.45 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $299.20 | 2019-2021 | |
| Abbott Laboratories | $280.25 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $279.58 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $247.63 | 2024-2025 | Zenpep |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Levyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.